Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

A Mechanism of Resistance to Antibody-Targeted Immune Attack.

Aldeghaither DS, Zahavi DJ, Murray JC, Fertig EJ, Graham GT, Zhang YW, O'Connell A, Ma J, Jablonski SA, Weiner LM.

Cancer Immunol Res. 2019 Feb;7(2):230-243. doi: 10.1158/2326-6066.CIR-18-0266. Epub 2018 Dec 18.

PMID:
30563830
2.

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.

Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, Shimizu E.

Clin Cancer Res. 2007 Mar 1;13(5):1552-61.

3.

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, Caraglia M.

Eur J Cancer. 2010 Jun;46(9):1703-11. doi: 10.1016/j.ejca.2010.03.005.

PMID:
20399639
4.

Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.

Cheng ZJ, Garvin D, Paguio A, Moravec R, Engel L, Fan F, Surowy T.

J Immunol Methods. 2014 Dec 1;414:69-81. doi: 10.1016/j.jim.2014.07.010. Epub 2014 Jul 31.

PMID:
25086226
5.

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.

Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F.

Int J Cancer. 2014 May 1;134(9):2146-55.

6.
7.

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.

Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M.

MAbs. 2014 Mar-Apr;6(2):409-21. doi: 10.4161/mabs.27457. Epub 2013 Dec 11.

8.

Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.

Gottschalk N, Kimmig R, Lang S, Singh M, Brandau S.

Int J Mol Sci. 2012;13(9):12000-16. doi: 10.3390/ijms130912000. Epub 2012 Sep 20.

9.

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.

Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C.

Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90. doi: 10.1016/j.critrevonc.2015.02.014. Epub 2015 Mar 12. Review.

PMID:
25819749
10.

IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.

Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X.

Hum Antibodies. 2010;19(4):89-99. doi: 10.3233/HAB-2010-0232.

PMID:
21178280
11.

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.

López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL.

Cancer Immunol Immunother. 2009 Nov;58(11):1853-64. doi: 10.1007/s00262-009-0697-4. Epub 2009 Mar 25.

12.

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.

Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, Mordoh J, Levy EM.

Breast Cancer Res Treat. 2011 Nov;130(2):465-75. doi: 10.1007/s10549-011-1360-2. Epub 2011 Feb 10.

PMID:
21308409
13.

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.

Jain A, Poonia B, So EC, Vyzasatya R, Burch EE, Olsen HS, Mérigeon EY, Block DS, Zhang X, Schulze DH, Hanna NN, Twadell WS, Yfantis HG, Chan SL, Cai L, Strome SE.

Eur J Cancer. 2013 Oct;49(15):3344-52. doi: 10.1016/j.ejca.2013.06.009. Epub 2013 Jul 18.

PMID:
23871153
14.

B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.

Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.

Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6.

PMID:
20056126
15.

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.

Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.

16.

Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.

Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM.

Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353. Epub 2015 Apr 7.

17.

IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.

Kubach J, Hubo M, Amendt C, Stroh C, Jonuleit H.

Int J Cancer. 2015 Feb 15;136(4):821-30. doi: 10.1002/ijc.29037. Epub 2014 Jun 26.

18.

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.

Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y.

Oncol Rep. 2014 May;31(5):2115-22. doi: 10.3892/or.2014.3077. Epub 2014 Mar 11.

PMID:
24626880
19.

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K.

Cancer Sci. 2007 Aug;98(8):1275-80. Epub 2007 May 13.

20.

Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.

Oppenheim DE, Spreafico R, Etuk A, Malone D, Amofah E, Peña-Murillo C, Murray T, McLaughlin L, Choi BS, Allan S, Belousov A, Passioukov A, Gerdes C, Umaña P, Farzaneh F, Ross P.

Br J Cancer. 2014 Mar 4;110(5):1221-7. doi: 10.1038/bjc.2014.35. Epub 2014 Feb 4.

Supplemental Content

Support Center